Business
Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
The event will begin today at 11:30 a.m. ET Event to feature Dr. Shahrokh Shabahang, Chie...
About this update from Appili Therapeutics Inc Class A
[{"type":"text","content":"Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n \n\n\n\n\n The event will begin today at 11:30 a.m. ET\n \n\n\n\n Event to feature Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt; Chris Mitton, President of Pearsanta; and Dr. Roger Giese, Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University\n \n\n\n\n\n Aditxt, Inc. (NASDAQ: ADTX), (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. (“Pearsanta”). The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and other illnesses. The discussion will explore the platform’s role in advancing Pearsanta’s mission to address cancer through early detection and prevention.\n \n\n\n Featured participants will include:\n \n\n\n\n\n Dr. Shahrokh Shabahang\n \n , Chief Innovation Officer, Aditxt\n \n\n\n Chris Mitton\n \n , President, Pearsanta\n \n\n\n Dr. Roger Giese\n \n , Co-Inventor of the CaSe Platform and Professor Emeritus, Northeastern University\n \n\n\n\n Event Details:\n \n\n\n Title:\n \n Aditxt Weekly Update\n \n\n Date:\n \n Friday, March 28, 2025\n \n\n Time:\n \n 11:30 a.m. ET\n \n\n Location:\n \n Virtual (Zoom)\n \n\n Registration:\n \n\n Click here to register\n \n\n\n\n About Pearsanta\n \n\n\n Pearsanta is at the forefront of precision health, focusing on early cancer detection through advanced diagnostic technologies. Its proprietary Mitomic Technology Platform leverages the unique properties of mitochondrial DNA to detect cancer and other diseases with high accuracy via non-invasive, blood-based liquid biopsy tests. Pearsanta's asset portfolio also includes a range of other innovative diagnostic technologies, all aimed at transforming early disease detection and monitoring, enabling more informed treatment decisions and ultimately improving patient outcomes. For more information, please...